Limits...
MFTZ-1 reduces constitutive and inducible HIF-1α accumulation and VEGF secretion independent of its topoisomerase II inhibition.

Dai M, Miao ZH, Ren X, Tong LJ, Yang N, Li T, Lin LP, Shen YM, Ding J - J. Cell. Mol. Med. (2010)

Bottom Line: In this study, we further examined the effects of MFTZ-1 on hypoxia-inducible factor-1α (HIF-1α) accumulation, vascular endothelial growth factor (VEGF) secretion and angiogenesis.Mechanistic studies revealed that MFTZ-1 did not affect the degradation of HIF-1α protein or the level of HIF-1α mRNA.The results reveal an important feature that MFTZ-1 can reduce constitutive, HIF-1α-independent VEGF secretion and concurrently antagonize inducible, HIF-1α-dependent VEGF secretion.

View Article: PubMed Central - PubMed

Affiliation: Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.

Show MeSH

Related in: MedlinePlus

MFTZ-1 decreases HIF-1α protein accumulation. MDA-MB-231 cells were exposed to hypoxia for the indicated times (A), to hypoxia and gradient concentrations of MFTZ-1 for 6 hrs (B) and to pre-starved MDA-MB-231 cells were exposed to the indicated concentrations of MFTZ-1 for 4 hrs after stimulated by epidermal EGF (50 ng/ml) for 4 hrs at normoxia (C). (D) HC T116, A375, A549, MDA-MB-468 and HeLa cells were treated with the indicated concentrations of MFTZ-1 at hypoxia for 6 hrs. Then the cells were collected and detected for HIF-1α and β-Actin by Western blotting. All data shown were representative of three independent experiments.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822569&req=5

fig01: MFTZ-1 decreases HIF-1α protein accumulation. MDA-MB-231 cells were exposed to hypoxia for the indicated times (A), to hypoxia and gradient concentrations of MFTZ-1 for 6 hrs (B) and to pre-starved MDA-MB-231 cells were exposed to the indicated concentrations of MFTZ-1 for 4 hrs after stimulated by epidermal EGF (50 ng/ml) for 4 hrs at normoxia (C). (D) HC T116, A375, A549, MDA-MB-468 and HeLa cells were treated with the indicated concentrations of MFTZ-1 at hypoxia for 6 hrs. Then the cells were collected and detected for HIF-1α and β-Actin by Western blotting. All data shown were representative of three independent experiments.

Mentions: Our previous study shows that MFTZ-1 has an averaged IC50 of 0.99 μM for the exposure duration of 72 hrs in MDA-MB-231 cells [13]. In this study, we found MFTZ-1 to be non- to sub-cytotoxic (growth inhibition <20%vs control) to MDA-MB-231 cells in the range of 0.008 μM to 1 μM for 6 hrs and 16 hrs (data not shown). To examine whether MFTZ-1 decreases the level of cellular HIF-α protein, we used these concentrations of the compound to treat human cancer cells under various conditions. When human breast cancer MDA-MB-231 cells were exposed to hypoxia (1% O2), the level of HIF-1α protein first rose, peaked at the time-point of 6–16 hrs, and then came down (Fig. 1A). Treatment of the cells with MFTZ-1 in hypoxia led to concentration-dependent reduction of cellular HIF-1α protein (Fig. 1B). Similarly, MFTZ-1 also abrogated the accumulation of HIF-1α protein driven by the growth factors EGF (Fig. 1C), which are known to stimulate the expression of HIF-1α protein [5, 6, 25]. Moreover, the levels of HIF-1α protein at hypoxic conditions were diminished by MFTZ-1 in a panel of tumour cell lines with different tissues of origin including breast cancer MDA-MB-468, colon cancer HCT-116, lung cancer A549, melanoma A375 and cervical cancer HeLa cell lines (Fig. 1D). In addition, MFTZ-1 was not revealed to inhibit HIF-2α in SKBr3 and 786-O cells (Fig. S4; HIF-2α was undetectable in MDA-MB-231 cells under the same condition). All these substantiate a universal reduction of HIF-1α protein induced by MFTZ-1 under the complicated conditions including tumour cells with different tissues of origin, normoxia, hypoxia, and stimulation with growth factors, most of which occur in the human body.


MFTZ-1 reduces constitutive and inducible HIF-1α accumulation and VEGF secretion independent of its topoisomerase II inhibition.

Dai M, Miao ZH, Ren X, Tong LJ, Yang N, Li T, Lin LP, Shen YM, Ding J - J. Cell. Mol. Med. (2010)

MFTZ-1 decreases HIF-1α protein accumulation. MDA-MB-231 cells were exposed to hypoxia for the indicated times (A), to hypoxia and gradient concentrations of MFTZ-1 for 6 hrs (B) and to pre-starved MDA-MB-231 cells were exposed to the indicated concentrations of MFTZ-1 for 4 hrs after stimulated by epidermal EGF (50 ng/ml) for 4 hrs at normoxia (C). (D) HC T116, A375, A549, MDA-MB-468 and HeLa cells were treated with the indicated concentrations of MFTZ-1 at hypoxia for 6 hrs. Then the cells were collected and detected for HIF-1α and β-Actin by Western blotting. All data shown were representative of three independent experiments.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822569&req=5

fig01: MFTZ-1 decreases HIF-1α protein accumulation. MDA-MB-231 cells were exposed to hypoxia for the indicated times (A), to hypoxia and gradient concentrations of MFTZ-1 for 6 hrs (B) and to pre-starved MDA-MB-231 cells were exposed to the indicated concentrations of MFTZ-1 for 4 hrs after stimulated by epidermal EGF (50 ng/ml) for 4 hrs at normoxia (C). (D) HC T116, A375, A549, MDA-MB-468 and HeLa cells were treated with the indicated concentrations of MFTZ-1 at hypoxia for 6 hrs. Then the cells were collected and detected for HIF-1α and β-Actin by Western blotting. All data shown were representative of three independent experiments.
Mentions: Our previous study shows that MFTZ-1 has an averaged IC50 of 0.99 μM for the exposure duration of 72 hrs in MDA-MB-231 cells [13]. In this study, we found MFTZ-1 to be non- to sub-cytotoxic (growth inhibition <20%vs control) to MDA-MB-231 cells in the range of 0.008 μM to 1 μM for 6 hrs and 16 hrs (data not shown). To examine whether MFTZ-1 decreases the level of cellular HIF-α protein, we used these concentrations of the compound to treat human cancer cells under various conditions. When human breast cancer MDA-MB-231 cells were exposed to hypoxia (1% O2), the level of HIF-1α protein first rose, peaked at the time-point of 6–16 hrs, and then came down (Fig. 1A). Treatment of the cells with MFTZ-1 in hypoxia led to concentration-dependent reduction of cellular HIF-1α protein (Fig. 1B). Similarly, MFTZ-1 also abrogated the accumulation of HIF-1α protein driven by the growth factors EGF (Fig. 1C), which are known to stimulate the expression of HIF-1α protein [5, 6, 25]. Moreover, the levels of HIF-1α protein at hypoxic conditions were diminished by MFTZ-1 in a panel of tumour cell lines with different tissues of origin including breast cancer MDA-MB-468, colon cancer HCT-116, lung cancer A549, melanoma A375 and cervical cancer HeLa cell lines (Fig. 1D). In addition, MFTZ-1 was not revealed to inhibit HIF-2α in SKBr3 and 786-O cells (Fig. S4; HIF-2α was undetectable in MDA-MB-231 cells under the same condition). All these substantiate a universal reduction of HIF-1α protein induced by MFTZ-1 under the complicated conditions including tumour cells with different tissues of origin, normoxia, hypoxia, and stimulation with growth factors, most of which occur in the human body.

Bottom Line: In this study, we further examined the effects of MFTZ-1 on hypoxia-inducible factor-1α (HIF-1α) accumulation, vascular endothelial growth factor (VEGF) secretion and angiogenesis.Mechanistic studies revealed that MFTZ-1 did not affect the degradation of HIF-1α protein or the level of HIF-1α mRNA.The results reveal an important feature that MFTZ-1 can reduce constitutive, HIF-1α-independent VEGF secretion and concurrently antagonize inducible, HIF-1α-dependent VEGF secretion.

View Article: PubMed Central - PubMed

Affiliation: Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.

Show MeSH
Related in: MedlinePlus